Zimmer Biomet Holdings, Inc. (NYSE:ZBH) released its quarterly earnings results on Monday. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02), Bloomberg Earnings reports. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the firm posted $1.79 EPS.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Investors of record on Friday, September 22nd were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend was Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is 27.59%.
A number of research firms recently commented on ZBH. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. BMO Capital Markets reiterated a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Wells Fargo & Company reiterated a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Morgan Stanley raised their price objective on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $125.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has a consensus rating of “Hold” and a consensus price target of $136.55.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/01/zimmer-biomet-holdings-inc-zbh-posts-earnings-results-misses-expectations-by-0-02-eps.html.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.